These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 9085540)

  • 1. Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review.
    Soderdahl DW; Wettlaufer JN; Corn B; Gomella LG
    Tech Urol; 1996; 2(4):194-206. PubMed ID: 9085540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H; Lau W; Bergstralh E; Blute ML
    J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
    Wieder JA; Soloway MS
    J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
    Noguchi M; Noda S; Nakashima O; Kojiro M
    Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
    Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
    Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
    Debruyne FM; Witjes WP
    Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prostate cancer].
    Fujii Y; Fukui I
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1740-4. PubMed ID: 18030007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?
    Scolieri MJ; Altman A; Resnick MI
    J Urol; 2000 Nov; 164(5):1465-72. PubMed ID: 11025684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is neoadjuvant hormonal therapy before radical prostatectomy indicated?
    Chun J; Pruthi RS
    Urol Int; 2004; 72(4):275-80. PubMed ID: 15153722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant hormone therapy: the Canadian trials.
    Klotz L; Gleave M; Goldenberg SL
    Mol Urol; 2000; 4(3):233-7;discussion 239. PubMed ID: 11062379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant hormonal therapy plus surgery for prostate cancer. The MSKCC experience.
    Fair WR; Scher HI
    Surg Oncol Clin N Am; 1997 Oct; 6(4):831-46. PubMed ID: 9309096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difficulties in interpreting specimens after neoadjuvant hormonal therapy and radiation with illustration of neuroendocrine differentiation.
    Civantos F
    Mol Urol; 2000; 4(3):117-21; discussion 123. PubMed ID: 11062365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
    Villavicencio Mavrich H; Chéchile Toniolo G; Salinas Duffo D; Muñoz Plaza J; Sorraca Ibáñez YJ
    Arch Esp Urol; 1996 Oct; 49(8):797-806. PubMed ID: 9065276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
    Garzotto M; Wajsman Z
    J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy.
    Andriole GL
    Eur Urol; 1997; 32 Suppl 3():65-9. PubMed ID: 9267788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
    Pfitzenmaier J; Altwein JE
    Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.